【罗氏制药与默克达成战略合作,推进中国肺癌精准治疗】3月26日,罗氏制药和默克共同宣布双方正式签订协议,就特泊替尼在中国大陆市场的商业化达成合作。特泊替尼是全球首个获批上市的MET抑制剂,于2023年12月在中国获批上市,通过靶向METex 14跳跃突变等特定靶点,用于非小细胞肺癌患者的精准治疗。

金融界
26 Mar
3月26日,罗氏制药和默克共同宣布双方正式签订协议,就特泊替尼在中国大陆市场的商业化达成合作。特泊替尼是全球首个获批上市的MET抑制剂,于2023年12月在中国获批上市,通过靶向METex 14跳跃突变等特定靶点,用于非小细胞肺癌患者的精准治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10